3 Firms Lead CERo Therapeutics $145M SPAC Merger
Immunotherapy company CERo Therapeutics Inc. and special-purpose acquisition company Phoenix Biotech announced on Monday that they would merge, taking CERo public at a value of $145 million, advised by Cooley LLP,...To view the full article, register now.
Already a subscriber? Click here to view full article